Of note, clinical trials of the MCT1 inhibitor AZD3965 in diffuse large B cell lymphoma and Burkitt’s lymphoma, two typical MYC-driven cancer types, are currently ongoing.105. This evidence concerns the gene MYC and Burkitt lymphoma.